PROF.DR.IR., Professor, Amsterdam UMC
Biography
Charlotte Teunissen’s drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, often by –omics methods, followed by biomarker assay development and analytical validation, and lastly, extensive clinical validation and implementation of novel biomarkers in clinical practice. She has extensive expertise with assay development on state of the art technologies, such as mass spectrometry and antibody-based arrays for biomarker discovery, ultrasensitive immunoassays, and in in implementation of vitro diagnostic technologies for clinical routine lab analysis. She is responsible for the large well-characterised biobank of the Amsterdam Dementia cohort, containing >5200 paired CSF and serum samples of individuals visiting the memory clinical of the Alzheimer Center Amsterdam (a.o. controls, patients with Alzheimer, Frontotemporal, Lewy Bodies).To ensure the quality of the biosamples, the group studies pre-analytical effects, which are key to implementation. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers consortia. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers (10 academic centers + 10 non-academic centers), and the JPND bPRIDE project, that aims to develop targeted blood based biomarker panels for early differential diagnoses of specific dementias and is a collaborative project between 7 European and 1 Australian centers.
Session Abstract – PMWC 2022 Silicon Valley
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.
Sessions:
- 4th Generation Sequencing Technologies & Genome Mapping Systems
- Barrett Bready, Nabsys
- Alka Chaubey, Bionano Genomics
- Eli Glezer, Singular Genomics - Long-Read Sequencing Technologies
- Steve Turner, PacBio - Single Cell Genomics
- Michael Schnall-Levin, 10x Genomics - Spatial Transcriptomics
- Jason T. Gammack, Resolve Biosciences - Pathogen Identification
Session Chair: Charles Chiu, UCSF
- Philip Stevens, Noscendo - Metagenomics and Microbial Profiling
- Amrie Grammer, Ampel BioSolutions - ML/AI for Diagnosis & Prognosis
- Todd Dickinson, Arc Bio - Modern Technologies for Pathogen Identification + AI
Session Chair: Sivan Bercovici, Karius Dx - Novel SBS Methodology
- Josh Lauer, Ultima Genomics - Proteogenomics
- Nigel Beard, Encodia - Advances Proteomics - Stratifying Cardiovascular Risk to Decrease Cost of Care
Session Chair: Roy Smythe, SomaLogic
- Adrian Lee, UPMC
- Jamie Bauersmith, UPMC - Leveraging Immune System Diagnostics to Improve Disease Outcomes
Session Chair: Kathy Kamath, Serimmune, Inc
- Noah Nasser, Serimmune, Inc
- Sasha Tabachnikova, Yale - Evolving Alzheimer’s Disease Therapeutics with Neuro Diagnostic Therapies (PANEL)
Session Chair: Kevin Hrusovsky, Quanterix
- Charlotte Teunissen, Amsterdam UMC
- Henrik Zetterberg, University of Gothenburg
- Nicholas Ashton, University of Gothenburg - PMWC Showcase (NCI)
- Michael Cardone, Eutropics Pharmaceuticals
- Robert Meltzer, Fluent BioSciences
- Cynthia Taylor Lawley, Olink Proteomics
- Niro Ramachandran, Akoya Biosciences
- Asim Siddiqui, Seer
